Best fit
Best fit is an enterprise team with a defined drug discovery and molecular design workflow, a measurable outcome, an accountable owner, and the capacity to run a controlled pilot.
Category framework
Drug discovery and molecular design AI products
Compare drug discovery and molecular design products on intended use, evidence, oversight, integration, governance, and market readiness.
Reviewed 2026-07-27. We do not publish universal winners.
Enterprise buying job
Find and prioritise promising targets, molecules, and biological hypotheses with a traceable research process.
Primary buyer: Chief scientific officer, discovery, computational biology, translational science, and research leaders.
Value case: Increase search and experiment capacity while keeping data quality, reproducibility, and scientific judgement explicit.
Quick answer: This category is for chief scientific officer, discovery, computational biology, translational science, and research leaders.. The safest shortlist starts with intended use, evidence scope, workflow oversight, and market diligence. Use the glossary when a term needs clarification.
Questions to answer before a shortlist
- What measurable life outcome should improve, and what must never be automated?
- Which evidence is independent, current, and relevant to the exact intended use?
- Who owns exceptions, incidents, model changes, supplier assurance, and user training?
What a serious comparison should cover
- Clear intended use, accountable outcome, and boundary conditions
- Evidence quality, limitations, validation, and monitoring
- Human review, exception handling, auditability, and recovery
- Integration, identity, data portability, resilience, and support
- Privacy, security, fairness, accessibility, and governance readiness
Material risks
- A vendor demonstration does not establish performance in the buyer's data, workflow, or market.
- Automation can move risk rather than remove it if review, escalation, or ownership is unclear.
- Privacy, security, accessibility, procurement, and change-management requirements must be assessed locally.
Sources and further reading
Buyer decision profile
Turn the shortlist into a governed decision.
The ranking is only a starting point. Use this profile to decide whether to pilot, what to measure, and who must own the risk.
Not a fit when
It is not a fit when the buyer wants a generic AI promise, has no owner for exceptions and outcomes, or cannot provide the data, integration, review, and governance needed for safe operation.
Stakeholders
- Chief scientific officer, discovery, computational biology, translational science, and research leaders.
- Security, privacy, legal, procurement, and enterprise architecture
- Frontline users and the people accountable for customer or operational outcomes
Implementation prerequisites
- A signed intended-use statement and baseline measures
- Data, identity, integration, and environment readiness
- Training, human review, escalation, monitoring, and rollback ownership
Pilot measures
- Time saved or cycle-time change without quality regression
- Exception, override, escalation, and error rates
- User adoption, customer or stakeholder outcomes, and control effectiveness
Commercial questions
- What is priced by user, volume, data, model, workflow, or outcome?
- What support, assurance, audit, portability, and exit rights are included?
- How are model, feature, hosting, and supplier changes communicated and tested?
Next diligence action: Choose one bounded drug discovery and molecular design workflow, document the current baseline, request the vendor evidence pack, and run a time-boxed pilot with a named business and risk owner.
Market questions
The same category changes by country.
Use the country guides to put this framework into a local regulatory and procurement context.
US
United States
What US rules, procurement controls, and customer-impact obligations apply to drug discovery and molecular design?
Open market guideUK
United Kingdom
What UK regulatory, data, professional, and procurement evidence is required for drug discovery and molecular design?
Open market guideEU
European Union
How do EU AI, privacy, sector, and member-state obligations affect drug discovery and molecular design?
Open market guideAU
Australia
What Australian regulatory, privacy, resilience, and local availability checks apply to drug discovery and molecular design?
Open market guideA practical next step
Could a focused app fit the drug discovery and molecular design workflow?
This page compares drug discovery and molecular design products. Enterprise AI Group can also help a team define a focused application around its own process, users, systems, and review points.
Enterprise AI Group describes a 6–8 week path for a defined workflow. Timing and cost depend on scope, users, integrations, security, governance, and support. These research pages are published by Enterprise AI Group. The implementation links describe optional Enterprise AI Group services; they are not product endorsements or a replacement for local life diligence.
Explore Enterprise AI solutionsDo not include personal, confidential, regulated, or other sensitive information in an enquiry.
Verified comparison
Public enterprise evidence, ranked within this category.
Scores show the completeness and strength of evidence available at the review date. Open every profile before using the ranking to shape a shortlist.
- #1 Recursion 3.9
3.9
| Rank | Product | What it does | Evidence status | Score (rounded) |
|---|---|---|---|---|
| 1 | Recursion | Tech-enabled drug discovery using biology, automation, and machine learning. | Evidence-backed | 3.9 / 5 |
Decision-support boundary: Scores are displayed to one decimal, but category order and shared ties use the unrounded weighted total. This is an evidence-maturity comparison, not a product-fit or universal-winner ranking: peers may support different sub-jobs and are not assumed to be substitutes. Portfolio records assess public evidence at the named portfolio level; do not transfer evidence between modules, versions, configurations, or markets. This page is not professional advice, legal confirmation, educational endorsement, confirmation of local availability, or a substitute for formal diligence. Verify intended use, accessibility, privacy, data handling and residency, security, procurement, contracting, implementation, and current product scope with the supplier and relevant authorities.
Research queue
Products still need evidence before comparison.
These records identify the product scope to investigate. They are not recommendations, rankings, reviews, or proof of outcomes.
Schrödinger
Schrödinger
Product-specific evidence has not been verified for publication.
Open official product scopeInsilico Medicine
Insilico Medicine
Product-specific evidence has not been verified for publication.
Open official product scopeBenevolentAI
BenevolentAI
Product-specific evidence has not been verified for publication.
Open official product scopeGenerate:Biomedicines
Generate:Biomedicines
Product-specific evidence has not been verified for publication.
Open official product scopeAtomwise
Atomwise
Product-specific evidence has not been verified for publication.
Open official product scopeProduct evidence profiles
Why each verified product scored as it did.
These concise profiles separate the intended enterprise job from the evidence and limitations recorded at the review date.
Rank 1 · reviewed 2026-07-27
Recursion
Recursion
3.9 / 5
Tech-enabled drug discovery using biology, automation, and machine learning.
Scope evidence: This product description is anchored to Recursion product information (vendor evidence). This link supports product scope, not a universal educational or commercial claim.
- Primary buyer
- Chief scientific officer, discovery, computational biology, translational science, and research leaders.
- Intended use
- Use Recursion for a bounded drug discovery and molecular design workflow, with the intended output, accountable owner, review point, and stop rule written down before a pilot.
- Enterprise fit
- Potential fit for teams that need a governed workflow for tech-enabled drug discovery using biology, automation, and machine learning and can provide the data, integration, domain owner, user training, human review, and supplier controls required for a pilot.
- Deployment
- Start with one drug discovery and molecular design process and a named accountable owner from chief scientific officer, discovery, computational biology, translational science, and research leaders. Confirm the exact module, edition, model or automation features, data boundary, identity model, integrations, support, monitoring, accessibility, and rollback process before production use.
- Evidence status
- Evidence-backed
How it could be used
Recursion: bounded drug discovery and design pilot using verified evidence
A buyer wants to test whether Recursion can support tech-enabled drug discovery using biology, automation, and machine learning in a bounded drug discovery and design workflow without moving an accountable decision into an opaque or unreviewable system. The source record supplies evidence to test, not a promised result.
- 1
Define one drug discovery and design job, its users, inputs, expected outputs, baseline, and actions the product must never take.
- 2
Record the exact Recursion module, edition, model, connector, version, permissions, and data boundary used in the test.
- 3
Run representative cases and have a named domain owner review outputs, errors, uncertainty, accessibility, and exceptions before any consequential action.
- 4
Compare results with the current process and retain accepted, corrected, escalated, rejected, and manually completed cases.
- 5
Decide whether the evidence supports a larger pilot, a narrower use, a watchlist entry, or stopping the evaluation.
Expected outcome
Measure a change in the current drug discovery and design baseline, such as cycle time, quality, workload, exception handling, user effort, or control effectiveness. No improvement is assumed from the product description or case study.
Controls to show in a pilot
- Named business, domain, security, privacy, procurement, and technical owners.
- Human approval for consequential outputs, with visible override and escalation routes.
- Input and output logging with access control, retention, correction, and incident handling.
- A manual fallback, stop rule, rollback path, and review of changes to the product, model, data, or supplier.
Reviews and evidence
- Official Recursion scope source Vendor evidence · Verified source
The official Recursion source anchors the product scope. It is not treated as independent proof of performance, safety, value, or local readiness.
Open the source - Peer-reviewed industrialised drug-discovery method paper Independent review · Verified source
The peer-reviewed Drug Factory paper describes an industrialised, data-generating loop for high-content screening, machine learning, automation, and experimental feedback, using Recursion as a concrete example. It is scientific and company-affiliated evidence about a method, not proof that every programme or candidate succeeds.
Open the sourceWhy this matters: It lets a research buyer assess the real operating model: AI drug discovery is valuable only when data generation, wet-lab validation, reproducibility, and decision ownership are connected.
- Reviewer context
- August Allen and Lina Nilsson are named authors in the peer-reviewed SLAS Discovery paper; the paper identifies the Recursion context. Named peer-reviewed drug-discovery and translational-science authors.
- Organisation context
- The paper uses Recursion’s industrialised discovery approach as an example and discusses high-throughput experimental data, automation, and feedback loops. Size basis: The paper describes an industrialised company-scale operating model, but does not provide a customer-size comparison.
- Scope and sentiment
- exact product scope; positive signal; vendor involvement disclosed.
- Source trust
- 5/5. Named authors, peer-reviewed scientific publication, explicit workflow and methodological framing are strong; company affiliation and example-based scope limit independence and outcome generalisation. 1.00 context weight.
- Implementation context
- The paper explains how physical experiments become data and model feedback; scientific validation, reproducibility, translational success, regulatory review, and programme-specific outcomes remain open.
- Nature high-content imaging and machine-learning field context Independent review · Verified source
Nature’s field overview explains how machine learning and high-content imaging are being used for target discovery, hit identification, and toxicity testing across the industry. It provides important independent context for Recursion’s approach, but does not evaluate Recursion as a product vendor.
Open the sourceWhy this matters: It helps a buyer compare scientific method and validation requirements across vendors instead of treating one platform’s proprietary vocabulary as proof of better discovery.
- Reviewer context
- Nature Research is the named scientific publisher; the article is an industry field overview rather than a customer review. Independent scientific and industry editorial source.
- Organisation context
- The article discusses multiple companies and research approaches in AI-enabled high-content imaging and drug discovery. Size basis: The source is cross-industry and does not provide one organisation-size band.
- Scope and sentiment
- adjacent product scope; mixed signal; not disclosed.
- Source trust
- 4/5. Recognised scientific publisher and cross-company context strengthen the field signal; it is an overview and not a product benchmark. 0.36 context weight.
- Implementation context
- The article places the platform approach in the wider discovery field and highlights the need for biological validation; it is not evidence of a particular programme outcome.
Public product visual references
Public product visual reference: The official Recursion page is the visual reference for the named product scope. It is not an independent usability, accessibility, security, or safety audit.
Open screenshot sourceBuyer questions
- Which exact Recursion module, edition, model, connector, and version is being proposed, and which source supports that scope?
- Which evidence matches the buyer’s workflow, market, organisation size, and implementation maturity, and what was independently verified?
- Which reported benefits are vendor or commissioned claims, what were the baselines, and what limitations or negative findings must be reproduced?
- How are permissions, data retention, human approval, incident response, supplier changes, and exit or portability handled?
Score rationale
Outcome fit 15% 5 / 5
The evidence directly covers AI-enabled high-content screening, data generation, design, validation, and drug-development workflows.
Evidence 20% 4 / 5
Peer-reviewed method evidence and independent field context are strong, but clinical translation, reproducibility, and programme-level outcomes remain distinct gates.
Oversight 15% 4 / 5
The workflow explicitly couples models with physical experiments and scientific review, but programme governance and decision criteria remain buyer-specific.
Integration 20% 5 / 5
The platform scope and method paper describe integrated experimental, data, modelling, and feedback loops.
Governance 15% 3 / 5
Scientific data and programme controls matter, but the public evidence does not establish a buyer’s data-sharing, IP, privacy, access, or regulatory configuration.
Markets 15% 2 / 5
The platform has enterprise and biopharma collaboration evidence, but buyer-specific licensing, data, partnership, support, and regulatory readiness remain open. This industry record has no documented local commercial or support evidence in this batch, so the market score is capped at 2.
Limitations to verify
- The evidence is specific to the named Recursion scope, sources, workflows, versions, and organisations; it does not establish a universal product outcome.
- Commissioned research and vendor-published cases are disclosed and weighted below independent evidence; reported metrics are not forecasts.
- Local availability, data handling, security, privacy, accessibility, support, procurement, contract terms, and qualified domain review remain buyer-specific publication and pilot gates.
Public assessment history
- 2026-07-27: A product-specific evidence record now separates official scope from independent review leads and defines a bounded buyer workflow. Human review must verify the underlying review context before any score or recommendation is published. Reviewer role: Human product and domain review required before scoring. Changed fields: product scope, evidence record, review source leads, workflow example, market diligence notes, score status. Changed dimensions: intended-use-outcome-fit, evidence-safety-maturity, workflow-human-oversight, integration-operability, security-privacy-governance, market-readiness.
- 2026-07-27: Removed generated grammar artefacts and verb repetition from a watchlist record while preserving its research-queue publication status and unassessed scores. Reviewer role: Editorial copy-quality review; product evidence and domain review remain required before publication.. Changed fields: buyer-fit language, deployment language, bounded workflow language. Changed dimensions: copy quality and evidence boundary.
- 2026-07-27: Applied named customer, analyst, and independent review evidence with bounded claims; qualified editorial and domain review remains required before treating the record as a recommendation. Reviewer role: Evidence research prepared for qualified human editorial and domain review. Changed fields: evidenceStatus, sources, reviews, scores, marketRecords, limitations. Changed dimensions: intended-use-outcome-fit, evidence-safety-maturity, workflow-human-oversight, integration-operability, security-privacy-governance, market-readiness.
Market evidence
United States limited
United States availability, configuration, support, contract, data handling, and intended-use evidence must be checked against the buyer's deployment. This evidence batch documents public product and implementation material, not a local commercial, residency, support, or regulatory approval.
United Kingdom limited
United Kingdom availability, configuration, support, contract, data handling, and intended-use evidence must be checked against the buyer's deployment. This evidence batch documents public product and implementation material, not a local commercial, residency, support, or regulatory approval.
European Union limited
European Union availability, configuration, support, contract, data handling, and intended-use evidence must be checked against the buyer's deployment. This evidence batch documents public product and implementation material, not a local commercial, residency, support, or regulatory approval.
Australia limited
Australia availability, configuration, support, contract, data handling, and intended-use evidence must be checked against the buyer's deployment. This evidence batch documents public product and implementation material, not a local commercial, residency, support, or regulatory approval.
Sources
- Recursion product information vendor evidence
- Recursion Operating System platform scope vendor evidence
- The Drug Factory: industrialising drug discovery independent evidence
- Nature overview of machine learning and high-content cell imaging independent evidence
- Recursion Roche and Genentech collaboration announcement vendor evidence
How to use this page
A product source is not a recommendation.
Start with intended use and your own workflow, then use the market notes, limitations, and linked sources to define a diligence plan. Read the full comparison method before interpreting any published score.
Keep the useful part
Tell us what you are deciding next.
Send the life workflow, market, or category you are researching. We will use it to shape the next clear buyer brief.
Useful detail: include the market, workflow, or category behind Drug discovery and molecular design shortlist.
Please do not send personal, confidential, regulated, or other sensitive information.